This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/chemspider/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n28http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/pharmgkb/
n12http://www.rxlist.com/cgi/generic/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/property/
n10http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00324/identifier/drugbank/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00324
rdf:type
n3:Drug
n3:description
A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
n3:dosage
n11:271B54AC-363D-11E5-9242-09173F13E4C5 n11:271B54AD-363D-11E5-9242-09173F13E4C5 n11:271B54AE-363D-11E5-9242-09173F13E4C5 n11:271B54AF-363D-11E5-9242-09173F13E4C5 n11:271B54B0-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
n3:manufacturer
n5:271B5495-363D-11E5-9242-09173F13E4C5 n5:271B5496-363D-11E5-9242-09173F13E4C5 n5:271B5497-363D-11E5-9242-09173F13E4C5 n5:271B5498-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00324 n28:DB00324
dcterms:title
Fluorometholone
adms:identifier
n18:DB00324 n19:9494 n20:9878 n21:D01367 n22:11980-228-05 n23:46505984 n24:PA164781355 n25:Fluorometholone
n3:mechanismOfAction
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Their primary target is the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.
n3:packager
n5:271B5493-363D-11E5-9242-09173F13E4C5 n5:271B5494-363D-11E5-9242-09173F13E4C5 n5:271B5491-363D-11E5-9242-09173F13E4C5 n5:271B5492-363D-11E5-9242-09173F13E4C5 n5:271B548F-363D-11E5-9242-09173F13E4C5 n5:271B5490-363D-11E5-9242-09173F13E4C5 n5:271B548D-363D-11E5-9242-09173F13E4C5 n5:271B548E-363D-11E5-9242-09173F13E4C5 n5:271B548B-363D-11E5-9242-09173F13E4C5 n5:271B548C-363D-11E5-9242-09173F13E4C5 n5:271B548A-363D-11E5-9242-09173F13E4C5
n3:synonym
NSC 33001 Fluor-OP Fluorometholonum Fluorometholon Fluorometolona Oxylone (1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one Fluorometholone 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione Fluorométholone
n3:toxicity
Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD<sub>50</sub> = 234 mg/kg (rats)
n6:hasAHFSCode
n30:52-08-08
n3:mixture
n4:271B5487-363D-11E5-9242-09173F13E4C5 n4:271B5488-363D-11E5-9242-09173F13E4C5 n4:271B5486-363D-11E5-9242-09173F13E4C5 n4:271B5489-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation. 
Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company
. Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company. 
Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.
n13:hasConcept
n14:M0008628
foaf:page
n10:fml1183.shtml n12:fluorometholone.htm n29:fluorometholone.html
n3:IUPAC-Name
n8:271B54B5-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B54BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B54BA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B54B7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B54B8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B54B9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B54CB-363D-11E5-9242-09173F13E4C5 n8:271B54B3-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B54CD-363D-11E5-9242-09173F13E4C5 n8:271B54B1-363D-11E5-9242-09173F13E4C5 n8:271B54B4-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B54CE-363D-11E5-9242-09173F13E4C5 n8:271B54B2-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:D07AB06 n7:D10AA01 n7:D07XB04 n7:C05AA06 n7:S01BA07 n7:S01CB05
n3:H-Bond-Acceptor-Count
n8:271B54C1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B54C2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B54BC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B54BD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B54BF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B54BE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B54C0-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
426-13-1
n3:category
n3:containedIn
n15:271B54AB-363D-11E5-9242-09173F13E4C5 n15:271B54A9-363D-11E5-9242-09173F13E4C5 n15:271B54AA-363D-11E5-9242-09173F13E4C5 n15:271B54A7-363D-11E5-9242-09173F13E4C5 n15:271B54A8-363D-11E5-9242-09173F13E4C5 n15:271B54A5-363D-11E5-9242-09173F13E4C5 n15:271B54A6-363D-11E5-9242-09173F13E4C5 n15:271B54A3-363D-11E5-9242-09173F13E4C5 n15:271B54A4-363D-11E5-9242-09173F13E4C5 n15:271B54A1-363D-11E5-9242-09173F13E4C5 n15:271B54A2-363D-11E5-9242-09173F13E4C5 n15:271B549F-363D-11E5-9242-09173F13E4C5 n15:271B54A0-363D-11E5-9242-09173F13E4C5 n15:271B549D-363D-11E5-9242-09173F13E4C5 n15:271B549E-363D-11E5-9242-09173F13E4C5 n15:271B549B-363D-11E5-9242-09173F13E4C5 n15:271B549C-363D-11E5-9242-09173F13E4C5 n15:271B5499-363D-11E5-9242-09173F13E4C5 n15:271B549A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B54C7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B54C9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B54CA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B54CC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B54C6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B54C5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B54C8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B54B6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B54C3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B54C4-363D-11E5-9242-09173F13E4C5